US regulatory filing shows Sorbent Therapeutics gains nearly maximum round to treat renal problems.
Sorbent Therapeutics, a US-based kidney treatment company, has raised $16.8m of a $21.8m series B round from 10 investors, according to a regulatory filing with the Securities and Exchange Commission.
William Rajski, founder and chief financial officer at Sorbent, said the full amount had been raised with $16.8m invested at the end of June and ther remaining $5m "to be received prior to January 15", confirming a report by news provider MedCity, which revealed the filing.
Rajski added: "Sorbent…
